Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency ...

A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human ...

Nearly half of all new cases in 2022 were in the South. "The frustrating part is we have the tools now to stop it." ...

New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

A clinical trial suggests Lenacapavir, a yearly injection, could revolutionise HIV prevention by offering long-term protection, simplifying adherence, and expanding access to at-risk populations., Hea ...

The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...

Without urgent intervention, Kenya risks a surge in new HIV infections, which currently stand at 16,752 annually, NSDCC said.

Follow the latest news headlines from Australia's most trusted source. Read in-depth expert analysis and watch live coverage on ABC News.